Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
Revenue: Enanta reported Q2 revenue of $17.1 million, down from $17.8 million in the prior year.
Net Loss: The company posted a net loss of $31.2 million ($1.47 per share), an improvement from a $37.7 million loss last year.
Pipeline Progress: Data from the Phase II pediatric RSV study (RSVPEDs) is expected in the second half of 2024, and Phase IIa EDP-323 RSV data is anticipated in Q3 2024.
Expense Guidance: R&D expense guidance was raised to $125–145 million, and G&A expense guidance rose to $50–60 million, both reflecting increased pipeline investment.
Cash Position: Enanta ended the quarter with approximately $300 million in cash and marketable securities, expected to fund operations into Q3 2027.
Immunology Expansion: The company aims to select a KIT inhibitor candidate for CSU by Q4 2024 and introduce a second immunology program this year.
Patent Litigation: Legal expenses increased due to the ongoing patent infringement case against Pfizer, with a potential trial expected around year-end.
